Item Type | Name |
Concept
|
Acute Disease
|
Concept
|
Central Nervous System Diseases
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
Concept
|
Bone Marrow Diseases
|
Concept
|
Graft vs Host Disease
|
Concept
|
Hepatic Veno-Occlusive Disease
|
Concept
|
Graft Survival
|
Concept
|
Chronic Disease
|
Concept
|
Disease Susceptibility
|
Concept
|
Drug Therapy, Combination
|
Concept
|
Kidney Diseases
|
Concept
|
Graft Rejection
|
Concept
|
Hematologic Diseases
|
Concept
|
Hematopoietic Stem Cells
|
Concept
|
Duodenal Diseases
|
Concept
|
Esophageal Diseases
|
Concept
|
Nervous System Diseases
|
Concept
|
Lymphatic Diseases
|
Concept
|
Peripheral Nervous System Diseases
|
Concept
|
Hodgkin Disease
|
Concept
|
Recurrence
|
Concept
|
Stem Cells
|
Concept
|
Tumor Stem Cell Assay
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
Concept
|
Disease Management
|
Concept
|
Vascular Diseases
|
Concept
|
Stem Cell Transplantation
|
Concept
|
Neoplasm Recurrence, Local
|
Concept
|
Disease Progression
|
Concept
|
Hematopoietic Stem Cell Mobilization
|
Concept
|
Peripheral Blood Stem Cell Transplantation
|
Concept
|
Adult Stem Cells
|
Concept
|
Stomach Diseases
|
Concept
|
Stem Cell Niche
|
Concept
|
Graft vs Tumor Effect
|
Concept
|
Myeloid Progenitor Cells
|
Concept
|
Secondary Prevention
|
Concept
|
Induction Chemotherapy
|
Concept
|
Consolidation Chemotherapy
|
Concept
|
Cord Blood Stem Cell Transplantation
|
Concept
|
Arterial Occlusive Diseases
|
Concept
|
Liver Diseases
|
Concept
|
Pulmonary Veno-Occlusive Disease
|
Concept
|
Sigmoid Diseases
|
Concept
|
Neoplastic Stem Cells
|
Concept
|
Virus Diseases
|
Concept
|
Disease-Free Survival
|
Concept
|
Genetic Predisposition to Disease
|
Concept
|
Maintenance Chemotherapy
|
Academic Article
|
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
|
Academic Article
|
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
|
Academic Article
|
Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
|
Academic Article
|
Studies of minimal residual disease in acute lymphocytic leukemia.
|
Academic Article
|
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
|
Academic Article
|
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
|
Academic Article
|
Progressive transformation of germinal centers. Report of 2 cases and review of the literature.
|
Academic Article
|
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
|
Academic Article
|
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
|
Academic Article
|
Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?
|
Academic Article
|
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
|
Academic Article
|
Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning.
|
Academic Article
|
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
|
Academic Article
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
Academic Article
|
Controversies in treatment of AML: case-based discussion.
|
Academic Article
|
Gene expression changes associated with progression and response in chronic myeloid leukemia.
|
Academic Article
|
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
Academic Article
|
Progress in the treatment of adults with acute lymphoblastic leukemia.
|
Academic Article
|
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
|
Academic Article
|
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
Academic Article
|
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.
|
Academic Article
|
Clinical trials in adult AML.
|
Academic Article
|
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
|
Academic Article
|
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
|
Academic Article
|
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
|
Academic Article
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
Academic Article
|
Adult acute lymphoblastic leukemia: concepts and strategies.
|
Academic Article
|
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
|
Academic Article
|
Chimerism does not predict for outcome after alemtuzumab based conditioning.
|
Academic Article
|
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
|
Academic Article
|
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
|
Academic Article
|
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
|
Academic Article
|
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
|
Academic Article
|
Successful allogeneic transplantation of patients with suspected prior invasive mold infection.
|
Academic Article
|
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
|
Academic Article
|
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
|
Academic Article
|
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants.
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
|
Academic Article
|
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
|
Academic Article
|
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
|
Academic Article
|
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
|
Academic Article
|
Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).
|
Academic Article
|
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.
|
Academic Article
|
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
|
Academic Article
|
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
|
Academic Article
|
Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.
|
Academic Article
|
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
|
Academic Article
|
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
|
Academic Article
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
Academic Article
|
Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Minimal residual disease: current status in leukemia.
|
Academic Article
|
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
|
Academic Article
|
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
Academic Article
|
Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options.
|
Academic Article
|
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
|
Academic Article
|
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.
|
Academic Article
|
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Influence of related donor age on outcomes after peripheral blood stem cell transplantation.
|
Academic Article
|
Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
|
Academic Article
|
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
|
Academic Article
|
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
|
Academic Article
|
Immune reconstitution after combined haploidentical and umbilical cord blood transplant.
|
Academic Article
|
Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.
|
Academic Article
|
Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies.
|
Academic Article
|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
|
Academic Article
|
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.
|
Academic Article
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
Academic Article
|
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
|
Academic Article
|
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
|
Academic Article
|
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
|
Academic Article
|
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
|
Academic Article
|
Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
|
Academic Article
|
Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
|
Academic Article
|
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
|
Academic Article
|
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
|
Academic Article
|
Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.
|
Academic Article
|
Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
|
Academic Article
|
How I treat acute lymphoblastic leukemia in older adolescents and young adults.
|
Academic Article
|
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
|
Academic Article
|
Novel drug targets in acute leukemia.
|
Academic Article
|
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
|
Academic Article
|
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
|
Academic Article
|
Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?
|
Academic Article
|
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
Academic Article
|
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.
|
Academic Article
|
Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
|
Academic Article
|
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.
|
Academic Article
|
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
|
Academic Article
|
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
|
Academic Article
|
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
|
Academic Article
|
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
|
Academic Article
|
An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.
|
Academic Article
|
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
|
Academic Article
|
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
|
Academic Article
|
The Persistence of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: We Know It's Bad, Now What?
|
Academic Article
|
A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML).
|
Academic Article
|
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
|
Academic Article
|
Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.
|
Academic Article
|
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
|
Academic Article
|
Stem cell transplantation eliminates alloantibody in a highly sensitized patient.
|
Academic Article
|
Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.
|
Academic Article
|
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
|
Academic Article
|
Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach.
|
Academic Article
|
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.
|
Academic Article
|
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
Treatment of Acute Promyelocytic Leukemia in Adults.
|
Academic Article
|
Should immunologic strategies be incorporated into frontline ALL therapy?
|
Academic Article
|
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
|
Academic Article
|
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
Academic Article
|
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
|
Academic Article
|
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
|
Academic Article
|
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.
|
Academic Article
|
Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
|
Academic Article
|
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.
|
Academic Article
|
Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia.
|
Academic Article
|
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
|
Academic Article
|
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.
|
Academic Article
|
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Management of acute lymphoblastic leukemia in young adults.
|
Academic Article
|
Randomized trial of 10 days of decitabine ? bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
|
Academic Article
|
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.
|
Academic Article
|
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
|
Academic Article
|
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
|
Academic Article
|
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.
|
Academic Article
|
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
|
Academic Article
|
Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
|
Academic Article
|
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
|
Academic Article
|
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
|
Academic Article
|
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
|
Academic Article
|
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
|
Academic Article
|
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
|
Academic Article
|
Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
|
Academic Article
|
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
|
Academic Article
|
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
|
Academic Article
|
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
|
Academic Article
|
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.
|
Academic Article
|
Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
|
Academic Article
|
Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study.
|
Academic Article
|
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
|
Academic Article
|
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.
|
Academic Article
|
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
|
Academic Article
|
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
|
Academic Article
|
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults.
|
Academic Article
|
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
|
Academic Article
|
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
|
Academic Article
|
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
|
Academic Article
|
New Approaches to Treating Challenging Subtypes of ALL in AYA Patients.
|
Academic Article
|
Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.
|
Academic Article
|
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
|
Academic Article
|
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
|
Academic Article
|
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
|
Academic Article
|
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
|
Academic Article
|
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.
|
Academic Article
|
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
|
Academic Article
|
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
|
Academic Article
|
Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia.
|
Academic Article
|
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
|
Academic Article
|
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).
|
Academic Article
|
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
|
Academic Article
|
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.
|
Academic Article
|
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
|
Academic Article
|
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
|
Academic Article
|
Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia.
|
Academic Article
|
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
|
Academic Article
|
Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!
|
Academic Article
|
Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.
|
Academic Article
|
Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents.
|
Academic Article
|
D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemia.
|
Academic Article
|
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
|
Academic Article
|
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
|
Academic Article
|
[Inguinal hernia repair modified by Kirschner. A critical analysis after 11 years of clinical experience].
|
Academic Article
|
[Is the surgeon a prognostically relevant factor after R0-resection of colorectal carcinoma?].
|
Academic Article
|
Does methodic long-term follow-up affect survival after curative resection of colorectal carcinoma?
|
Academic Article
|
[Surgical therapy of sigmoid diverticulitis in elderly patients.--What decides against early elective resection].
|
Academic Article
|
[Value of individually risk-adjusted after-care--economic management of oncologic effectiveness?].
|
Academic Article
|
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
|
Academic Article
|
[Preoperative esophagogastroduodenoscopy before elective surgical therapy of symptomatic cholelithiasis].
|
Academic Article
|
[Follow-up in stomach carcinoma].
|
Academic Article
|
[Individual risk-related after-care in colorectal cancer?].
|
Academic Article
|
Ultrasonic endoluminal examination in the follow-up of colorectal cancer. Initial experience and results.
|
Academic Article
|
CGG-repeat polymorphism of the BCR gene rules out predisposing alleles leading to the Philadelphia chromosome.
|
Academic Article
|
[Acceptance and effectiveness of surgical vascular consultation--is it worthwhile?].
|
Academic Article
|
[Psychological stress on patients in tumor after-care after R0 resection of colorectal carcinomas].
|
Academic Article
|
[Results of regular follow-up after removal of colorectal adenomas].
|
Academic Article
|
A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
|
Academic Article
|
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
|
Academic Article
|
[Surgical treatment of large thoracic wall recurrences in breast cancer].
|
Concept
|
Transplant Recipients
|